Syndicate Market Research

Global Cancer Diagnostics Market Analysis, Trends, Segment & Forecast Up to 2020

Cancer Diagnostics Market


Deerfield Beach, FL -- (SBWIRE) -- 05/03/2016 -- Cancer is a disease that includes abnormal growth of cells. These cells have potential to spread across other parts of the body. Malignant tumor or malignant neoplasm are the another names given to the cancer. Gene variation affecting critical cell-regulatory proteins is primarily responsible for cancer. Tobacco, sun exposure, chemicals, alcohol, infectious organisms, etc. are the external factors responsible for gene variations in a human body.

Browse Full Report @

The cancer diagnostics market is mainly is driven by the rising incidences of cancer. Growing healthcare expenditure is another key factor to drive the cancer diagnostics market. Governments and Global Health Organizations take initiatives to spread awareness about cancer. This has fueled the growth of global cancer diagnostics market. However, some issues like high cost treatment is expected to hamper growth of cancer diagnostics industry.

The global cancer diagnostics market is segmented on the basis of methods of treatment, application and region. Based on different methods, market is segmented as tumor biomarker tests, imaging, endoscopy, and biopsy. Imaging treatment for cancer diagnostics dominated the cancer diagnostics market due to its demand almost from every cancer type. Imaging for cancer detection is further classified into magnetic resonance imaging (MRI) scan, positron emission tomography (pet) scan, computed tomography (ct) scan, mammography, ultrasound methods.

The report provides a comprehensive view on the cancer diagnostics market we have included a detailed company market share analysis, product portfolio of the major industry participants. To understand the competitive landscape in the market, an analysis of Porter's Five Forces model for the cancer diagnostics market has also been included. The study encompasses a market attractiveness analysis, wherein application segments are benchmarked based on their market size, growth rate and general attractiveness.

Get Request Sample @

Application segments have been analyzed based on historic, present, and future trends, and the market has been estimated from 2015 to 2020 in terms of revenue (USD Million). Blood cancer, breast cancer, colorectal cancer (CRC), kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer are the application segments of cancer diagnostics market from which lung cancer application segment holds highest market share in terms of revenue.

Major regional segments analyzed in this study include North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. This report also provides further bifurcation of region on the country level. Major countries analyzed in this reports are U.S., Germany, France, UK, China, Japan, India, and Brazil. Cancer diagnostics market was dominated by North America in 2014. Europe is followed by North America. The Asia Pacific is expected grow cancer diagnostics market due to increasing prevalence of breast cancer in this region.

Some of the key players for global cancer diagnostics market includes Abbott Diagnostics, AstraZeneca, Pfizer, Ambry Genetics, Myriad Genetics, F. Hoffmann-La Roche Ltd., and Eli Lily Co.

Get Illustrative Sample before buying:

This report segments the global cancer diagnostics market as follows:
Global Cancer Diagnostics Market: Method Segment Analysis
- Tumor Biomarker Tests
- Imaging
- Endoscopy
- Biopsy
Global Cancer Diagnostics Market: Application Segment Analysis
- Blood Cancer
- Breast Cancer
- Colorectal Cancer (CRC)
- Kidney Cancer
- Liver Cancer
- Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
Global Cancer Diagnostics Market: Regional Segment Analysis
- North America
o U.S.
- Europe
o UK
o France
o Germany
- Asia Pacific
o China
o Japan
o India
- Latin America
o Brazil
- Middle East & Africa

Contact US
3422 SW 15 Street, Suit #8138,
Deerfield Beach,Florida 33442,
USATel: +1-386-310-3803GMT Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651